4:42 PM
 | 
May 28, 2019
 |  BioCentury  |  Finance

NanoDimension adding European focus for new $335M fund

With third fund, NanoDimension planning its first-ever European investments while doubling down on therapeutics

NanoDimension intends to make its first-ever investments in Europe from its new $335 million third fund, with far more global emphasis on drug development than its previous funds have had.

The California-based firm has established an office in Lausanne, Switzerland, from which two partners will manage investments. European and American LPs, including family offices as well as undisclosed institutional investors, contributed to the fund, which is more than twice the size of NanoDimension’s last vehicle. Two partners in California will continue to shepherd U.S. investments.

Dani Bach told BioCentury he believes Europe offers opportunities equal in quality to that in the U.S., but at lower valuations. Bach joined NanoDimension this year after...

Read the full 539 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >